Source / Disclosures
Disclosures: Barouch claims to be co-inventor of related vaccine patents. Please see the study for relevant financial information from all other authors.
Data now published in a major journal shows that the Johnson & Johnson COVID-19 vaccine generated high activity against SARS-CoV-2 for at least 8 months, including against variants of concern.
The results were published today in a correspondence to The New England Journal of Medicine, several weeks after Johnson & Johnson reported them in a press release and researchers submitted them to a preprint server.
In the newspaper, Dan H. Barouche, MARYLAND, Doctorate, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and professor of medicine at Harvard Medical School, and colleagues report 8-month durability of humoral and cellular immune responses in 20 people who received the Johnson & Johnson vaccine in one or two doses, and five people who received a placebo.
According to the study, they assessed the antibody and T cell responses of 10 people 8 months after receiving a single dose of the vaccine, and 10 people 6 months after receiving two doses. They also tested the performance of the vaccine against wild-type SARS-CoV-2 and alpha (B.1.1.7), kappa (B.1.617.1), delta (B.1.617.2), gamma (P . 1), epsilon (B.1.429) and beta (B.1.351).
Barouch and colleagues reported detection of antibody responses in all vaccine recipients by day 239, with the median titer of binding antibody against the wild-type SARS-CoV-2 receptor binding domain reaching 645 by day. 29, 1772 on day 57, 1962 on day 71, and 1306 on day 239. The median titer of neutralizing antibodies to the WA1 / 2020 virus-like virus was 272 on day 29, 169 on day 57, 340 on day 71 and 192 on day 239, and titers were similar when analyzes were limited to participants who had received the single-injection vaccination schedule, the researchers said.
In addition, the study found that three recipients of the vaccine had a sharp increase in antibody responses during the study period, including one who had a breakthrough infection that was “minimally symptomatic” and two who had received a vaccine. to messenger RNA. Exclusion of these participants showed that antibody responses were relatively stable over the 8-month period, with a reduction in median neutralizing antibody titer by a factor of 1.8 between peak response on day 71 and the timing of the sustainability assessment at day 239, Barouch and colleagues said.
According to the study, the dosed recipients had a median neutralizing antibody titer of 184 against the wild strain, 158 against the D614G variant, 147 against the alpha variant, 171 against the kappa variant, 107 against the delta variant, 129 against the gamma variant, 87 against the epsilon variant and 62 against the beta variant at day 239. The researchers said that these data suggest “an expansion in the extent of neutralizing antibodies” associated with improved coverage of the SARS- variants. CoV-2 over time, including increased neutralizing antibody titers against these variants of concern.
“These data show that the Ad26.COV2.S vaccine elicited lasting humoral and cellular immune responses with minimal decreases for at least 8 months after vaccination,” they wrote. “The durability of humoral and cellular immune responses following Ad26.COV2.S vaccination with increased neutralizing antibody responses to SARS-CoV-2 variants over time, including after single injection vaccination, further supports the use of the Ad26.COV2.S vaccine to fight the global COVID-19 pandemic.